menu
    • menu
    [{"orgOrder":0,"company":"ABL Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SOUTH KOREA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"ABL301","moa":"IGF-1 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"ABL Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ABL Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"ABL Bio \/ Inapplicable"},{"orgOrder":0,"company":"ABL Bio","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Antibody","year":"2022","type":"Collaboration","leadProduct":"ABL301","moa":"IGF-1 receptor","graph1":"Neurology","graph2":"Preclinical","graph3":"ABL Bio","amount2":1.0600000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":1.0600000000000001,"dosageForm":"Undisclosed","sponsorNew":"ABL Bio \/ Sanofi","highestDevelopmentStatusID":"4","companyTruncated":"ABL Bio \/ Sanofi"}]

    Find Clinical Drug Pipeline Developments & Deals for ABL301

    Menu

    ABL301

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ABL Bio

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed

                            ABL Bio

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABL301

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            This is a Study to Evaluate the Safety, Tolerability, PK and PD of IV Administered ABL301 in Healthy Adult Par...

                            Details : Undisclosed

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 07, 2023

                            Lead Product(s) : ABL301

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            ABL Bio

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed

                            ABL Bio

                            South Korea arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ABL301

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Sanofi

                            Deal Size : $1,060.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of P...

                            Details : ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease.

                            Product Name : Undisclosed

                            Product Type : Antibody

                            Upfront Cash : $75.0 million

                            November 01, 2022

                            Lead Product(s) : ABL301

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Sanofi

                            Deal Size : $1,060.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth